Treatment (as Prevention) Availability and Individuals' Behavior: A Cost-Effectiveness Analysis of Cabotegravir Long-Acting Injectable PrEP
{{output}}
Background: The US Food and Drug Administration (FDA) has approved long-acting injectable agents for preexposure prophylaxis (PrEP) of human immunodeficiency virus (HIV) infection. These agents are urgently required to enhance bo... ...
